诺和诺德公司公布的新一代糖尿病药物amycretin临床试验数据显示，该药物在降低血糖的同时实现显著减重效果，为这家 市值今年蒸发过半的丹麦制药商带来提振。 周二，诺和诺德发布的试验结果显示，amycretin注射剂每周给药一次，可在36周内帮助患者减轻最多14.5%的体重，而每 日口服制剂的减重幅度可达10.1%。 Shah补充道： 不过，诺和诺德试验中的患者体重更重，而体重较重的人群初期减重可能相对容易。 Shah认为： 在大型后期研究中，amycretin对血糖的影响小于礼来公司的药物，但包括副作用在内的详细数据将是关键。 据报道，Amycretin是诺和诺德新一代药物组合中的关键一环，该药物将两种减重机制整合到单一分子中。 消息推动诺和诺德的美股股价收涨超4.6%，收复昨日Ozempic药物实验失败带来的大部分跌幅。 华尔街见闻提及，周一诺和诺德宣布，公司的Ozempic口服版本在两项大型临床试验中未能减缓阿尔茨海默症进展。基于认 知评估结果，服用该药物的患者并未出现显著好转。 而针对此次amycretin的实验结果，彭博行业研究分析师Michael Shah表示，尽管因临床试验设计不同难以直接比较， ...

Bernstein just threw fresh fuel on Eli Lilly's (LLY) never-ending rally, as the firm lifted its price target on the stock to $1,300 from $1,100. For perspective, that’s an 18% bump compared to the old target, while representing a 21% to 22% upside compared to Lilly’s current stock price. Analyst Courtney Breen feels Wall Street still isn't factoring in how massive the company’s next wave of GLP-1 catalysts could be. She feels Lilly’s incredible leap into the trillion-dollar club, as reported by Reuters, ...

周二，诺和诺德(NVO.US)股价逆市上涨，截至发稿，该股涨超2.9%，报46.3美元。消息面上，该公司 表示，其下一代减重与糖尿病候选药物amycretin在最新研究中展现显著疗效，不仅有效降低患者血糖， 还实现明显体重下降，为这家在减重市场竞争中承压的药企带来一线利好。 分析师Michael Shah表示，从减重效果看，amycretin的表现优于礼来(LLY.US)旗下的Zepbound以及次世 代口服药orforglipron，但由于试验设计不同，两者难以直接比较；此外，诺和诺德试验中的受试者整体 更重，而体重较高者在初期更容易出现较大幅度减重。 研究显示，患者每周注射一次amycretin，36周内体重平均下降幅度高达14.5%；若以口服方式、每日一 次服用，患者体重也平均下降10.1%。诺和诺德表示，这是该公司在下一代代谢类药物布局中的关键成 果。 ...

分析师Michael Shah表示，从减重效果看，amycretin的表现优于礼来(LLY.US)旗下的Zepbound以及次世 代口服药orforglipron，但由于试验设计不同，两者难以直接比较；此外，诺和诺德试验中的受试者整体 更重，而体重较高者在初期更容易出现较大幅度减重。 智通财经APP获悉，周二，诺和诺德(NVO.US)股价逆市上涨，截至发稿，该股涨超2.9%，报46.3美 元。消息面上，该公司表示，其下一代减重与糖尿病候选药物amycretin在最新研究中展现显著疗效，不 仅有效降低患者血糖，还实现明显体重下降，为这家在减重市场竞争中承压的药企带来一线利好。 研究显示，患者每周注射一次amycretin，36周内体重平均下降幅度高达14.5%；若以口服方式、每日一 次服用，患者体重也平均下降10.1%。诺和诺德表示，这是该公司在下一代代谢类药物布局中的关键成 果。 ...

We recently published Top 10 Non-AI Stocks Redditors are Buying Ahead of Potential Bubble Burst. Eli Lilly And Co (NYSE:LLY) is one of the top non-AI stocks redditors are buying. Eli Lilly And Co (NYSE:LLY) recently posted strong quarterly results amid robust growth from its diabetes and weight-loss products. With a diverse portfolio spanning oncology, immunology and neuroscience, Redditors believe the company can offset any potential weakness in GLP-1 drugs amid the US government’s push to lower prices. ...

整理 | GLP1减重宝典内容团队 2025年11月21日，礼来在Clinicaltrials.gov上双重注册了其小分子GLP-1受体激动剂orforglipron的三期ATTAIN-Outcomes试验，用于 评估动脉粥样硬化性心血管疾病（ASCVD）和/或慢性肾脏病（CKD）患者的心血管结局。 该三期研究计划入组7140名受试者，随访五年，预计2031年完成。 主要终点为主要不良心血管事件（MACE）。 | Brief Summary | Study Start (Estimated) 0 | | --- | --- | | The purpose of this study is to measure cardiovascular outcomes with orforglipron | 2026-01 | | compared with placebo in participants with atherosclerotic cardiovascular disease | | | (ASCVD) and/or chronic kidney disease (CKD). Participation ...

当地时间11月24日，诺和诺德宣布，公司的Ozempic口服版本在两项大型临床试验中未能减缓阿尔茨海默病进 展，这一被视为长远投资的尝试宣告失败。基于认知评估结果，服用该药物的患者并未出现显著好转。 消息公布后，诺和诺德股价周一在丹麦哥本哈根交易所一度暴跌超12%，触及2021年7月以来最低水平。当天 美股开盘后，其股价一度暴跌超9%，截至收盘，跌5.58%，总市值缩水至1996亿美元。 超级巨头突遭猛烈抛售。 美东时间11月24日，丹麦制药巨头诺和诺德美股股价遭遇重挫，盘中一度暴跌超9%。其股价当天在丹麦哥本 哈根交易所更是一度暴跌超12%。美股周二盘前，诺和诺德股价再度小幅走弱，现跌0.36%。消息面上，该公 司最新公布的临床试验数据显示，使用司美格鲁肽治疗早期阿尔茨海默病未见显著疗效，数千名参与研究的患 者均未出现明显改善。 有分析指出，对诺和诺德而言，阿尔茨海默病试验失败意味着又一起重大挫折。受下一代减肥药效果不及预 期、竞争对手蚕食市场份额等一系列利空消息影响，其股价年内累计跌幅已超46%。相比之下，诺和诺德在减 肥药领域的头号竞争对手——礼来公司股价则持续走高，成为第一家市值突破1万亿美元的制药公 ...

【深圳商报讯】（记者 钟国斌）11月21日，美国制药巨头礼来股价上涨1.59%，收报1059.70美元/股， 市值突破1万亿美元，成为全球首家市值破万亿美元的医药公司。 据了解，长期以来市值超过1万亿美元的公司几乎都是科技巨头。2018年，苹果成为美股首家万亿美元 的科技巨头，此后进入万亿美元俱乐部的9家企业中，7家均为科技类公司，只有"股神"巴菲特旗下的伯 克希尔·哈撒韦是个例外。如今，礼来成为第二家市值突破万亿美元的非科技类公司。 礼来股价上涨主要得益于旗下减重药物替尔泊肽（Tirzepatide）的热销。作为礼来目前的主力销售产 品，替尔泊肽可细分为治疗糖尿病的Mounjaro和针对肥胖症的Zepbound。数据显示，2023年，礼来公司 糖尿病版本Mounjaro销售额同比暴增970%，肥胖版本Zepbound上市首月即吸金1.76亿美元。 根据礼来上月公布的最新财报，Mounjaro三季度实现收入65.2亿美元，同比大增109%；Zepbound三季 度实现收入35.9亿美元，同比大增184%。三季度两款药物合计收入突破100亿美元，超越默沙东的K药 成为新晋"药王"。 礼来CEO戴夫·里克斯日前表 ...

Core Insights - GLP-1 medicines are experiencing significant growth in the pharmaceutical industry, particularly for weight management, with Eli Lilly and Novo Nordisk as the leading companies [1][6] - Eli Lilly's tirzepatide has rapidly become the world's best-selling drug, generating $24.8 billion in revenue in the first nine months of 2025 [2] - Eli Lilly is advancing its position with additional candidates like orforglipron and retatrutide, which could enhance its competitive edge in the GLP-1 market [4][5] Eli Lilly's Position - Eli Lilly's tirzepatide, marketed as Mounjaro and Zepbound, has cannibalized sales of its previous best-seller, Trulicity, and has shown effectiveness in multiple indications [1] - The drug mimics both GLP-1 and GIP hormones, leading to superior performance in weight management compared to competitors [3] - Eli Lilly has completed phase 3 studies for orforglipron, an oral GLP-1 medicine, which could be a first in the weight management category [4] - Retatrutide, currently in phase 3 studies, mimics three hormones and may further improve treatment efficacy [5] Novo Nordisk's Challenges - Novo Nordisk, previously the market leader, has seen its global market share decline from 55.7% to 49.3% as of August [7] - The company markets semaglutide under well-known brands like Ozempic and Wegovy but is struggling to keep pace with Eli Lilly's advancements [6][7]

Core Viewpoint - Eli Lilly has become the first pharmaceutical company to reach a market capitalization of $1 trillion, driven by strong demand for weight loss and diabetes medications, with its stock price rising nearly 40% this year [2][18]. Group 1: Market Performance - Eli Lilly's stock rose by 1.60% on Friday, contributing to a year-to-date increase of nearly 40% [2][3]. - The healthcare ETF in the U.S. has seen a rise of over 2% on Friday and a cumulative increase of 12% this year, reflecting growing investor enthusiasm for the pharmaceutical sector [5][6]. Group 2: Competitive Advantage - Eli Lilly is rapidly distancing itself from competitors due to the overwhelming advantage of its GLP-1 class drugs, with its weight loss drug Zepbound expected to dominate the market despite only launching at the end of 2023 [4][9]. - The company is on the brink of a significant new product cycle in biopharmaceuticals, with its oral weight loss candidate orforglipron being highlighted as one of the most important new product cycles in the industry [9][10]. Group 3: Future Prospects - Eli Lilly's management has indicated that global regulatory submissions for orforglipron are imminent, with expectations for a U.S. market launch next year [10]. - The company is also advancing in next-generation obesity compounds, with promising data from the second phase of the selective incretin agonist eloralintide, which showed a weight loss of 20.1% [11][12]. Group 4: Financial Considerations - Eli Lilly's largest shareholder, the Lilly Foundation, has been selling shares, with a record $2.4 billion in stock sold in Q4 2025, raising concerns about valuation [16][17]. - The company’s forward P/E ratio for 2026 is projected at 41 times, significantly higher than the pharmaceutical industry average of 16 times, leading to debates about its valuation [19]. - Forecasts suggest that Eli Lilly's two flagship drugs could generate annual sales exceeding $40 billion by 2026, potentially justifying the high valuation [20].